BVI Medical, a leading global ophthalmic device company at the forefront of advancements in eye surgery, announced the completion of a $1 billion strategic capital raise in partnership with TPG. This investment, which fully refinances BVI’s existing debt and adds new equity from both TPG and new investors, strengthens the company’s financial position as it looks to accelerate product innovation and expand its global footprint.
This financing also follows a period of accelerated momentum for BVI, during which the company has significantly grown its portfolio of product offerings and built one of the most robust product pipelines in the industry.
More recently, BVI expanded its IOL manufacturing in Europe to meet growing global demand, introduced new product lines such as SERENITY and SERENITY Toric premium monofocal IOLs, and strengthened its market position through strategic acquisitions.
KEY QUOTES:
“This investment marks a pivotal moment for BVI as we scale our capabilities to meet the rising demand for advanced ophthalmic solutions. We are redefining the future of eye surgery and changing the competitive landscape by driving the launch of breakthrough technologies that will empower surgeons worldwide.”
– Shervin Korangy, President and CEO
“TPG is proud to continue our partnership with BVI as it works to scale its global impact in ophthalmic care.”
– Kendall Garrison, Partner at TPG
“The company has strengthened its market position while advancing patient care worldwide and this investment will further drive innovation and expansion. We look forward to supporting BVI’s continued success.”
– John Schilling, MD, Co-Managing Partner at TPG Capital
